Retinal Drugs Market Updates

Global Retinal Drugs Market size was valued at USD 20.20 Billion in 2023 and is poised to grow from USD 21.86 Billion in 2024 to USD 41.06 Billion by 2032, growing at a CAGR of 8.2% during the forecast period (2025-2032).

The competitive landscape of the retinal drug market is marked by intense R&D, strategic acquisitions, and a race toward long-acting and gene-based therapies. Key players like Roche, Regeneron, and Novartis dominate with anti-VEGF therapies, while others like Sandoz and Coherus expand biosimilar portfolios. Merck’s acquisition of EyeBio and Astellas' purchase of Iveric Bio highlight growing M&A activity. Companies are also investing in implants and AI-driven diagnostics to boost adherence and outcomes. The landscape includes branded drugs, biosimilars, gene therapies, delivery innovations, and pipeline diversification—shaping a competitive, innovation-focused market poised for sustained growth. 'Roche Holding AG (incl. Genentech)', 'Regeneron Pharmaceuticals, Inc.', 'Novartis AG', 'Bayer AG', 'Allergan (AbbVie Inc.)', 'Alcon Inc.', 'Santen Pharmaceutical Co., Ltd.', 'MeiraGTx Holdings plc', 'Ocuphire Pharma, Inc.', 'Kodiak Sciences Inc.', 'Adverum Biotechnologies, Inc.', 'Oxurion NV', 'Graybug Vision, Inc.', 'Clearside Biomedical, Inc.', 'Outlook Therapeutics, Inc.', 'Iveric Bio (acquired by Astellas Pharma)', 'Sandoz (a Novartis spin-off for biosimilars)', 'Coherus BioSciences, Inc.', 'Biogen Inc.'

The growth of the retinal drug market is driven by advances in biologics and the growing portfolio of drug delivery systems. Anti-VEGF therapies have improved outcomes while reducing the treatment burden with fewer injections, with Eylea producing over $9.6 billion in 2023. Longer-lasting treatments like Susvimo's long-acting implant and gene therapies like Luxturna were just some examples of technologies that allow sustained treatments. With companies Roche and Novartis advancing clinical trials of several pipeline agents, and AI facilitating early diagnosis, there has never been more progress. All of these innovations of market potential enhance efficacy, lessen treatment burden, and provide access to a larger number of patients, all of which is a formula for growth in the market and delivery personalized treatments.

What Makes North America a Leader in Retinal Drugs?